Differential Diagnosis of Intestinal Tuberculosis (ITB) vs Crohn’s Disease (CD)

Differentiating Intestinal Tuberculosis (ITB) from Crohn’s Disease (CD) is one of the most challenging diagnostic dilemmas in clinical practice, particularly in tuberculosis (TB)-endemic regions. Both disorders share overlapping clinical, imaging, endoscopic, and histological features, but several distinct differences can guide the differential diagnosis. Below is a comprehensive breakdown of the key aspects for distinguishing ITB from CD:

---

### 1. **Epidemiological Context**

• **ITB**: More common in TB-endemic regions such as India, China, South Korea, Latin America, and South Africa.
• **CD**: Predominates in Western countries but is increasingly being reported in Asia, leading to overlap in these regions.

---

### 2. **Clinical Features**

• **Common Symptoms**: Both ITB and CD present with abdominal pain, obstruction, fever, anorexia, weight loss, and anemia, making symptoms alone insufficient for diagnosis.
• **Distinct Clues**:
• **ITB**: Ascites and pulmonary symptoms (e.g., cough, hemoptysis) are more common.
• **CD**: Diarrhea, rectal bleeding, perianal disease, and extraintestinal manifestations (e.g., skin, joints, eyes, hepatobiliary involvement) are more suggestive of CD.
• **Disease Duration**: ITB typically has a relatively acute course, while CD tends to have a more chronic and relapsing course.

---

### 3. **Imaging Features (CT Enterography)**

• **ITB**:
• Necrotic lymph nodes (central low attenuation with peripheral rim enhancement).
• Ileocecal involvement (most common site).
• Ascites and omental thickening.
• **CD**:
• Skip lesions (discontinuous areas of inflammation).
• Long-segment disease.
• Comb sign (engorged vasa recta).
• Mesenteric fat proliferation ("creeping fat").
• **Quantitative Biomarker**:
• A visceral-to-subcutaneous fat ratio >0.63 on CT favors CD with ~80% sensitivity and specificity.

---

### 4. **Chest Imaging**

• **ITB**: CT chest can double diagnostic sensitivity by identifying miliary lesions or necrotic mediastinal lymph nodes. Chest radiographs alone are insufficient.
• **CD**: Normal chest imaging; no specific findings.

---

### 5. **Endoscopic Findings**

• **ITB**:
• Transverse ulcers.
• Gaping ileocecal valve.
• **CD**:
• Longitudinal ulcers.
• Cobblestoning.
• Aphthous ulcers.
• Skip lesions.
• **Granuloma Distribution**:
• **ITB**: Granulomas are localized to the ileocecal region.
• **CD**: Granulomas can occur in any bowel segment, often involving the rectosigmoid region, which is rarely affected in ITB.

---

### 6. **Histopathology**

• **ITB**:
• Caseating granulomas (highly specific but low sensitivity, 13–40%).
• **CD**:
• Non-caseating granulomas that are small, poorly organized, or isolated.
• **Key Difference**:
• Caseating granulomas are a hallmark of ITB, while non-caseating granulomas are more typical of CD.

---

### 7. **Microbiological Tests**

• **ITB**:
• Acid-Fast Bacilli (AFB) stain and culture, GeneXpert, and PCR are specific but have low sensitivity (<25%).
• GeneXpert MTB/RIF is preferred for rapid detection.
• **CD**:
• No specific microbiological test available.

---

### 8. **Serological and Immune Markers**

• **ITB**:
• Interferon-Gamma Release Assay (IGRA) and Tuberculin Skin Test (TST) detect latent TB, not active ITB.
• **CD**:
• Limited utility of IGRA and TST in distinguishing CD from ITB in TB-endemic regions.
• **Emerging Markers**:
• Novel biomarkers like FOXP3+ Tregs and metabolomics show promise but remain experimental.

---

### 9. **Therapeutic Anti-TB Therapy (ATT) Trial**

• In TB-endemic regions, when diagnostic uncertainty persists, a therapeutic trial of anti-TB therapy (ATT) is initiated to avoid the risk of giving immunosuppressants to undiagnosed ITB patients.
• **Response to ATT**:
• **ITB**: Clinical improvement and mucosal healing after 8–12 weeks strongly suggest ITB.
• **CD**: May show temporary symptom relief but no endoscopic healing.
• **Non-Response to ATT**:
• If no healing is observed after 8–12 weeks and multidrug-resistant TB (MDR-TB) is excluded, the diagnosis should shift toward CD, and CD-specific therapy (immunosuppressants/biologics) should be initiated.

---

### 10. **Follow-Up and Monitoring**

• **ITB**:
• Fecal calprotectin decline at 2 months and definitive mucosal healing at 6 months confirm the diagnosis.
• **CD**:
• Persistent ulcers or high fecal calprotectin levels favor CD.

---

### 11. **Surgical or Laparoscopic Biopsies**

• Considered in cases where endoscopic or imaging-guided sampling fails, especially before initiating biologic therapy or in cases of inaccessible lesions.

---

### 12. **Role of Artificial Intelligence (AI) and Predictive Models**

• Machine learning models combining clinical, imaging, and histological data (e.g., Limsrivilai Bayesian model, Crohn’s Aid app) have achieved up to 92% diagnostic accuracy and show promise in aiding diagnosis in TB-endemic settings.

---

### Summary Table: Key Differences Between ITB and CD

| Feature | ITB | CD |

|-----------------------------|-------------------------------------------|------------------------------------------|

| **Epidemiology** | TB-endemic regions | Western countries, increasing in Asia |

| **Disease course** | Acute | Chronic |

| **Symptoms** | Pulmonary symptoms, ascites | Diarrhea, rectal bleeding, perianal disease, extraintestinal manifestations |

| **Endoscopic findings** | Transverse ulcers, gaping ileocecal valve | Longitudinal ulcers, cobblestoning, skip lesions |

| **Histopathology** | Caseating granulomas | Non-caseating granulomas |

| **Imaging (CTE)** | Necrotic lymph nodes, ascites, ileocecal involvement | Skip lesions, comb sign, mesenteric fat proliferation |

| **Microbiological tests** | AFB stain, GeneXpert, PCR (low sensitivity) | Not applicable |

| **Response to ATT** | Mucosal healing | No healing |

| **Fecal calprotectin** | Decline supports ITB | Persistent elevation favors CD |

---

### Conclusion:

The differential diagnosis of ITB and CD requires a multimodal approach that integrates clinical, imaging, endoscopic, histological, and microbiological findings. In cases of diagnostic uncertainty, a therapeutic trial of ATT and close follow-up with fecal calprotectin levels or repeat colonoscopy can help clarify the diagnosis. Emerging biomarkers and AI-based predictive models hold promise for improving diagnostic accuracy in the future.